Floatz logo

cb-839

CRC

Calithera Biosciences, IncPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

17 Active assets in the CRC cohort.

Asset / SponsorPhaseRating
Irinotecan
Chang Gung Memorial Hospital
Phase 2B
ngm707
NGM Biopharmaceuticals, Inc
Phase 2B
POLO-LIKE KINASE 1 INHIBITOR NMS-1286937
Cardiff Oncology
Phase 2B
ag-120
Fudan University
Phase 2CCC
GENETICALLY-MODIFIED ONCOLYTIC TYPE 5 ADENOVIRUS WHICH SELECTIVELY REPLICATES IN TUMOR CELLS CONTAINING DYSFUNCTIONAL P53 GENE (H101)
Jun Huang
Phase 2CCC

View all 21 →

Same molecule, other indications

cb-839 is also rated in:

KRAS Gene MutationDormant
CCC
Indicative ·
52 / 100
View asset →
Waldenstrom's Macroglobulinemia (WM)Dormant
CC
Indicative ·
47 / 100
View asset →
Non-Hodgkin's Lymphoma (NHL)Dormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →